tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Anus Diseases D001004 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Scleritis D015423 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schreier MH et al. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? 1993 Transplant. Proc. pmid:7679818
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Reyes J et al. Nutritional management of intestinal transplant recipients. 1993 Transplant. Proc. pmid:7680149
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
McCauley J The nephrotoxicity of FK506 as compared with cyclosporine. 1993 Curr. Opin. Nephrol. Hypertens. pmid:7532089
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Schweizer M et al. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. 1993 Biochem. Pharmacol. pmid:7680201
Hirao A et al. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. 1993 Blood pmid:7680241
Panis Y and Valleur P [Small intestine transplantation. Experimental and clinical results]. 1993 Ann Chir pmid:7504899
Tsai M et al. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. 1993 Eur. J. Immunol. pmid:7504992
Hendrickson BA et al. Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. 1993 Gene pmid:7505249
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Pancer Z et al. cDNA cloning of a putative protochordate FK506-binding protein. 1993 Biochem. Biophys. Res. Commun. pmid:7505578
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Fischer S et al. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). 1993 Biochemistry pmid:7505615
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Thomson AW et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. 1993 Autoimmunity pmid:7505632
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Rao PN et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. 1993 Transplant. Proc. pmid:7682366
McDiarmid SV et al. FK506 conversion for intractable rejection of the liver allograft. 1993 Transpl. Int. pmid:7507675
Tokunaga Y et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. 1993 Transpl. Int. pmid:7507676
Winkler M et al. Conversion from cyclosporin to FK 506 after liver transplantation. 1993 Transpl. Int. pmid:7507677
Wallemacq PE and Reding R FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. 1993 Clin. Chem. pmid:7693372
Nakamura T et al. Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. 1993 EMBO J. pmid:7693452
Higa A et al. Attenuation of epithelial injury in acute experimental colitis by immunomodulators. 1993 Eur. J. Pharmacol. pmid:7693488
McCauley J et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. 1993 Nephrol. Dial. Transplant. pmid:7508098
Schmitt J et al. Cloning and expression of a mouse cDNA encoding p59, an immunophilin that associates with the glucocorticoid receptor. 1993 Gene pmid:7693550
Nishikawa T et al. Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. 1993 Pharm. Res. pmid:7508108
Shafiee A et al. Enzymatic synthesis and immunosuppressive activity of novel desmethylated immunomycins (ascomycins). 1993 J. Antibiot. pmid:7693638
Keicho N et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. 1993 J. Antibiot. pmid:7693639
Iwasaki K et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. 1993 Res. Commun. Chem. Pathol. Pharmacol. pmid:7508138
Timerman AP et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. 1993 J. Biol. Chem. pmid:7693682
Schwaninger M et al. Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. 1993 J. Biol. Chem. pmid:7693684
Smith DF et al. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. 1993 J. Biol. Chem. pmid:7693698
Takeda Y et al. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. 1993 J. Cardiovasc. Pharmacol. pmid:7509973
Soldin SJ et al. Immunophilin receptors for immunosuppressive drugs. 1993 Ther Drug Monit pmid:7510077
Dickey JB et al. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. 1993 Cornea pmid:7684663
McMichael J et al. Computer-guided concentration-controlled trials in autoimmune disorders. 1993 Ther Drug Monit pmid:7510078
Francavilla A et al. Hepatic regeneration and growth factors. 1993 J Surg Oncol Suppl pmid:7684910
Connelly PR et al. Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. 1993 Biochemistry pmid:7684925
Wallemacq PE et al. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. 1993 Clin. Chem. pmid:7684956
Mochizuki M et al. A clinical trial of FK506 in refractory uveitis. 1993 Am. J. Ophthalmol. pmid:7685147
Ocain TD et al. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. 1993 Biochem. Biophys. Res. Commun. pmid:7685167
Asami M et al. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. 1993 Biochem. Biophys. Res. Commun. pmid:7685169
Fenton M and Kay JE Thapsigargin activates lymphocytes via a different pathway from ionomycin. 1993 Biochem. Soc. Trans. pmid:7510649
Koga T et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. 1993 Chest pmid:7686837
Renoir JM et al. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522118
Nishi M et al. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. 1993 Invest. Ophthalmol. Vis. Sci. pmid:7686893
Jung-Testas I et al. [Inhibition of the anti-glucocorticosteroid effect of RU486 on the growth of mouse fibroblasts in culture by the immunosuppressor kf506]]. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522119
Nishizawa S et al. Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. 1993 Neurosurgery pmid:7687044
Warty V et al. FK506 measurement: comparison of different analytical methods. 1993 Ther Drug Monit pmid:7687389
Iwata H et al. Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. 1993 Transplantation pmid:7687396
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Antoni FA et al. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. 1993 Biochem. Biophys. Res. Commun. pmid:7687429
Denesyuk AI et al. Comparison of conformations of cyclosporin A and macrolide FK506 fragments: localization of putative binding sites with phosphatase calcineurin. 1993 Biochem. Biophys. Res. Commun. pmid:7687433
McCauley J et al. Renal transplantation under FK 506 in African-Americans: early experience. 1993 Transplant. Proc. pmid:7689270
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
McMaster P and Buist L FK 506 in transplantation. 1993 Transplant. Proc. pmid:7689275
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Ohzato H et al. Serum interleukin-6 levels as an indicator of acute rejection after liver transplantation in cynomologous monkeys. 1993 Surg. Today pmid:7689373
Hacker J and Fischer G Immunophilins: structure-function relationship and possible role in microbial pathogenicity. 1993 Mol. Microbiol. pmid:7526121
Takahashi H and Iizuka H Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation. 1993 J. Dermatol. Sci. pmid:7511000
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Galvin F et al. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. 1993 Eur. J. Immunol. pmid:7678228
Foxwell BM et al. Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. 1993 Eur. J. Immunol. pmid:7678231
Hirai T et al. Prolonged lung allograft survival with a short course of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7678313
Piekoszewski W et al. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. 1993 Jul-Aug Drug Metab. Dispos. pmid:7690698
Kobayashi J et al. A new rat infection-heart transplant model: effect of infection on graft survival studies. 1993 Jul-Aug J. Heart Lung Transplant. pmid:7690253
Schreier MH Immunophilins and immunosuppression. 1993 Mar-Apr Clin. Exp. Rheumatol. pmid:7686830
Iwasaki K et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. 1993 Nov-Dec Drug Metab. Dispos. pmid:7507815
Fukuse T et al. Combined therapy with FK-506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508750
Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508752
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Morozumi K and Takeda A [Kidney disorders induced by immunosuppressive agents]. 1994 Nippon Naika Gakkai Zasshi pmid:7529294
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. 1994 Lancet pmid:7522297
Ishioka M et al. FK506 treatment of noninfectious uveitis. 1994 Am. J. Ophthalmol. pmid:7526689
Hamajima E et al. Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. 1994 Dig. Dis. Sci. pmid:7512015